About Theratome Bio

REGENERATIVE MEDICINE / CONVENTIONAL THERAPY

Theratome Bio is developing a portfolio of therapeutics derived from the secretome of adult stem cells.

Our lead product Thera-101 is an injectable biologic drug designed to be first-line therapy for ischemic brain injury, including stroke.  First-in-human clinical trial of Thera-101 is planned for 2018.

Theratome Bio
Stroke is the #1 cause of disability, and 4th leading cause of death
0
stroke victims per year
0
people die every day waiting for an organ transplant

Regenerative Medicine

Our Theratome Innovation is rooted in the
body’s natural healing process